aha.org14h
FDA approves first-in-class non-opioid painkiller
The Food and Drug Administration Jan. 30 announced it approved Journavx (suzetrigine) oral tablets, a first-in-class ...
FDA approves new type of non-addictive painkiller from Boston drug company
The drug represents a new pathway to treating people with pain due to surgeries or traumatic injuries, avoiding the addictive ...
phillyvoice.com9h
FDA approves non-opioid painkiller, first new class in decades
A new drug approved Thursday by the FDA offers pain management but is not addictive. Unlike opioids, it treats pain signals ...
New Atlas1d
FDA approves new class of painkiller – the first in more than 20 years
The US Food and Drug Administration has approved the use of a novel painkiller as an effective treatment for short-term ...
FDA approved the first new kind of pain medication in 27 years. Here’s how it works
The FDA just approved a new type of pain medication, and it's a non-opioid called suzetrigine that stops body pain at its ...
BioSpace20h
FDA Approves Vertex’s Journavx as First New Pain Drug in Decades
The greenlight for Journavx (suzetrigine), which comes on the heels of a $7.4 billion opioid settlement, could spark momentum ...
Hosted on MSN11h
FDA approves 1st new class of opioid-free painkillers in over 20 years
The FDA has approved Journavx, an oral medication for treating pain that doesn't target the brain like addictive opioids.
BioPharma Dive16h
A new, non-opioid pain drug is here. Getting it to patients could be agony.
After decades of research, Vertex Pharmaceuticals now has an approved pain medication. Can one of the world’s most powerful ...
FDA Approves the First Non-Opioid Pain Drug in 20 Years
The prescription pills, sold under the brand name Journavx and made by Vertex Pharmaceuticals, are taken twice a day and ...
FDA approves first new class of painkiller in 20 years, a non-addictive opioid alternative
The medication offers relatively modest pain relief, underscoring the challenges of finding new ways to manage pain.
FiercePharma21h
Axsome secures hard-fought FDA nod for rapid-acting migraine drug Symbravo
Meloxicam is a nonsteroidal, anti-inflammatory molecule developed with Axsome’s Molecular Solubility Enhanced Inclusion ...